塵肺病市場規模、佔有率和成長分析：按疾病類型、治療方法、診斷方法、疾病嚴重程度、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球塵肺病市場價值為 17.7 億美元，預計到 2025 年將成長至 18.2 億美元，到 2033 年將成長至 23.1 億美元，在預測期（2026-2033 年）內複合年成長率為 3.0%。

全球塵肺病市場涵蓋診斷、治療和職業健康服務，旨在預防和管理吸入礦物粉塵引起的肺部疾病。由於職業性肺病在礦工、建築工人和產業工人中仍然普遍存在，尤其是在安全法規較為寬鬆的地區，因此該市場至關重要。從基礎X光攝影到先進的高解析度電腦斷層掃描和生物標記檢測，技術的顯著進步反映了持續的技術創新和日益嚴格的監管措施。東南亞煤礦數位成像診斷平台的興起表明，全球對先進軟體的需求正在成長。此外，政府監管的加強和工人安全意識的提高促使企業投資於監控設備和醫療評估，從而刺激了技術提供者和服務諮詢公司的業務成長。

全球塵肺病市場促進因素

雇主和員工對塵肺病風險的認知不斷提高，促使他們採取更嚴格的安全措施並進行定期健康監測。這種認知的增強推動了對更先進的防護設備和通風系統的投資，並在高風險行業中培養了預防意識。因此，對診斷服務和治療的需求日益成長，市場擴張得益於早期檢測工作的廣泛實施和持續的患者管理方法。這種趨勢在傳統上面臨高暴露風險的職業領域尤其明顯，例如採礦、建設業和石材加工行業。

全球塵肺病市場的限制因素

全球塵肺病市場面臨許多限制因素，其中之一是監管機構對新療法和診斷工具實施的嚴格評估流程。這些嚴苛的核准流程要求提供全面的臨床證據和詳盡的合規文件，這可能會顯著延長創新技術上市所需的時間。因此，儘管市場對有效療法的需求日益成長，但製造商可能仍會猶豫是否投資研發新的解決方案，這限制了先進療法的普及，並阻礙了市場成長。此外，不同地區監管標準的差異也進一步加劇了跨國公司在多個市場同時推出產品的難度。

全球塵肺病市場趨勢

全球塵肺病市場正呈現與數位化醫療整合的顯著趨勢，其特點是採用遠端醫療平台、人工智慧影像分析和雲端病患登記系統等先進技術。這項轉變正在簡化塵肺病的診斷和治療流程，並透過創新設備實現對肺功能的持續遠端監測。這些進步提高了醫療機構間的數據共用能力，從而加速了知識轉移，並促進了個人化治療方案的提供。隨著數位化解決方案的日益普及，相關人員不僅期望患者療效得到改善，而且希望資源分配更加高效，這體現了塵肺病領域醫療服務模式的變革性轉變。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球塵肺病市場規模：依疾病類型分類

• 煤礦工人塵肺病（CWP）
• 肺炎
• 石棉肺
• 混合性塵肺
• 其他

全球塵肺病市場規模：依治療方法分類

• 藥物治療
  • 支氣管擴張劑
  • 皮質類固醇
  • 抗生素
  • 抗纖維化藥物
  • 其他
• 氧氣療法
• 肺康復
• 肺移植
• 支持性護理與症狀治療

全球塵肺病市場規模：依診斷方法分類

• 胸部X光檢查
• 高解析度電腦斷層掃描（HRCT）
• 肺功能檢查（PFTs）
• 支氣管鏡檢查和切片檢查
• 其他

全球塵肺病市場規模：依疾病嚴重程度分類

• 溫和的
• 緩和
• 嚴重/進行性大塊纖維化（PMF）

全球塵肺病市場規模：依最終用戶分類

• 醫院
• 呼吸系統醫療設備
• 工業健康中心
• 門診部

全球塵肺病市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球塵肺病市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• United Therapeutics Corporation
• GSK plc
• AstraZeneca PLC
• Sanofi SA
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Insmed Incorporated
• Pliant Therapeutics, Inc.
• Avalyn Pharma Inc.
• PureTech Health plc
• MannKind Corporation
• United Therapeutics Corporation
• Cipla Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zambon SpA

結論與建議

Global Pneumoconiosis Market size was valued at USD 1.77 Billion in 2024 and is poised to grow from USD 1.82 Billion in 2025 to USD 2.31 Billion by 2033, growing at a CAGR of 3.0% during the forecast period (2026-2033).

The global market for pneumoconiosis encompasses diagnostics, therapeutics, and occupational health services aimed at preventing and managing lung diseases linked to mineral dust inhalation. This market is critical as occupational lung diseases persist among miners, construction, and industrial workers, particularly in regions with lax safety regulations. Significant advancements from basic radiography to advanced high-resolution CT scans and biomarker tests reflect ongoing technological innovations and more stringent regulatory measures. The rise of digital imaging platforms in Southeast Asia's coal mines signals increased demand for sophisticated software globally. Furthermore, heightened implementation of occupational health programs, driven by stricter government regulations and enhanced worker safety awareness, compels companies to invest in monitoring devices and medical evaluations, thereby fostering growth for both technology providers and service consultants.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pneumoconiosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pneumoconiosis Market Segments Analysis

Global pneumoconiosis market is segmented by disease type, treatment type, diagnosis type, disease severity, end user, distribution channel and region. Based on disease type, the market is segmented into Coal Workers' Pneumoconiosis (CWP), Silicosis, Asbestosis, Mixed Dust Pneumoconiosis and Others. Based on treatment type, the market is segmented into Pharmacological Therapy, Oxygen Therapy, Pulmonary Rehabilitation, Lung Transplantation and Supportive & Symptomatic Care. Based on diagnosis type, the market is segmented into Chest X-ray, High-Resolution Computed Tomography (HRCT), Pulmonary Function Tests (PFTs), Bronchoscopy & Biopsy and Others. Based on disease severity, the market is segmented into Mild Pneumoconiosis, Moderate Pneumoconiosis and Severe/Progressive Massive Fibrosis (PMF). Based on end user, the market is segmented into Hospitals, Pulmonology Clinics, Occupational Health Centers and Ambulatory Care Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pneumoconiosis Market

The growing awareness among employers and employees regarding the risks associated with pneumoconiosis is leading to the adoption of stringent safety measures and routine health monitoring. This increased consciousness is boosting investments in protective gear and enhanced ventilation systems, and is cultivating a preventive mindset in high-risk industries. Consequently, there is a rise in demand for diagnostic services and treatment options, which facilitates market expansion through the widespread implementation of early detection initiatives and ongoing patient management approaches. This trend is particularly evident in occupational sectors such as mining, construction, and stone-cutting, which have traditionally faced higher exposure risks.

Restraints in the Global Pneumoconiosis Market

The global pneumoconiosis market faces significant constraints due to the strict evaluation processes mandated by regulatory agencies for new therapies and diagnostic tools. These rigorous approval pathways require comprehensive clinical evidence and detailed compliance documents, which can significantly prolong the time needed to introduce innovations. As a result, manufacturers may hesitate to invest in new solutions, restricting the availability of advanced treatment options and hindering market growth, despite an increasing demand for effective interventions. Additionally, discrepancies in regulatory standards among different regions further complicate the efforts of multinational companies aiming to launch synchronized products across various markets.

Market Trends of the Global Pneumoconiosis Market

The Global Pneumoconiosis market is witnessing a significant trend towards digital health integration, characterized by the adoption of advanced technologies like telemedicine platforms, AI-driven imaging analysis, and cloud-based patient registries. This shift is streamlining the diagnosis and management of pneumoconiosis, allowing for continuous remote monitoring of lung function through innovative devices. Such advancements are enhancing data sharing capabilities among healthcare institutions, thereby fostering accelerated knowledge transfer and personalized treatment options. As digital solutions gain traction, stakeholders foresee not only improved patient outcomes but also more efficient resource allocation, reflecting a transformative approach to care delivery in the pneumoconiosis landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pneumoconiosis Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Coal Workers' Pneumoconiosis (CWP)
• Silicosis
• Asbestosis
• Mixed Dust Pneumoconiosis
• Others

Global Pneumoconiosis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Therapy
  • Bronchodilators
  • Corticosteroids
  • Antibiotics
  • Antifibrotic Agents
  • Others
• Oxygen Therapy
• Pulmonary Rehabilitation
• Lung Transplantation
• Supportive & Symptomatic Care

Global Pneumoconiosis Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Chest X-ray
• High-Resolution Computed Tomography (HRCT)
• Pulmonary Function Tests (PFTs)
• Bronchoscopy & Biopsy
• Others

Global Pneumoconiosis Market Size by Disease Severity & CAGR (2026-2033)

• Market Overview
• Mild Pneumoconiosis
• Moderate Pneumoconiosis
• Severe/Progressive Massive Fibrosis (PMF)

Global Pneumoconiosis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Pulmonology Clinics
• Occupational Health Centers
• Ambulatory Care Centers

Global Pneumoconiosis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Pneumoconiosis Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pliant Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avalyn Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PureTech Health plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations